FDA panel recommends drug strictly for African-Americans

Share this article:
The FDA moved one step closer to approving the first drug marketed to a specific ethnic group yesterday when an agency panel recommended that NitroMed's BiDil be marketed for strictly treating black people with heart failure.
The drug has  raised questions about how marketing, regulatory and political considerations play a role in new drug development, with critics of NitroMed saying the company has managed the regulatory system and patent law, along with historical inequities to drive its product to market.
Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.